Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CART22-65s cells + huCART19 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CART22-65s cells | anti-CD22 CAR T cells CART22-65s|anti-CD22 CAR 4-1BB-TCRz CART22-65s | CD22 Immune Cell Therapy 15 | CART22-65s cells consist of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets CD22, and linked to 4-1BB (CD137) co-stimulatory domain and CD3 zeta chain, which potentially leads to lysis of tumor cells expressing CD22 and antitumor activity (NCI Drug Dictionary; Blood (2022) 140 (Supplement 1): 2376-2377). | |
huCART19 | huCTL019|CTL119|autologous anti-CD19 CAR-CD3zeta-4-1BB-expressing T cells | CD19 Immune Cell Therapy 65 | huCART19 comprise autologous T-cells engineered to express a humanized chimeric antigen receptor (CAR) that targets CD19, as well as CD3zeta chain and 4-1BB, which may result in increased T-cell response against CD19-expressing tumor cells (NCI Drug Dictionary, PMID: 38615142). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03620058 | Phase I | CART22-65s cells + huCART19 CART22-65s cells | CART22 Alone or in Combination With huCART19 for ALL | Active, not recruiting | USA | 0 |
NCT05674175 | Phase Ib/II | CART22-65s cells + huCART19 | Co-administration of CART22-65s and huCART19 for B-ALL | Recruiting | USA | 0 |